Namocell announced today that it has signed an agreement with Tomy Digital Biology to distribute Namocell’s Namo Single Cell Dispenser in Japan.
Financial details of the agreement were not disclosed.
Namocell’s microfluidic-based cell platforms dispense single cells into a 96-well plate in less than a minute, the company said. The firm added that its cell cartridges simplify sterile sorting and eliminate the potential for system clogging.
“The Japanese market is in need of a high-performance and cost-effective single-cell dispensing and sorting instrument that is at the same time gentle to the cell and easy to use,” Tomy CEO and President Kenjiro Tominaga said in a statement.
In December 2016, Namocell partnered with researchers at Massachusetts General Hospital to research circulating tumor cells using the Namo Single Cell Dispenser platform.
Namocell Inc. provides the fastest way to a single cell. We are a leading provider of single cell dispensing and sorting technology based in the Silicon Valley. Our proprietary microfluidic-based single cell platforms simplify and empower a wide range of life science research and clinical applications, such as cancer immunotherapy, cell line development, rare cell isolation, CRISPR, single cell genomics, and monoclonal antibody isolation.
About Tomy Digital Biology
TOMY Digital Biology Co., Ltd. is headquartered in Tokyo and is a well-known trading company for the life science research products in Japan. The company is committed to providing new technologies and solutions that will revolutionize life science research.